Nemus Bioscience Signs Agreement with Pharmaceuticals International Inc. to Develop Dosage Formulation for Human Dosing with NB1111 for Glaucoma

Source:  Nemus Bioscience, Inc. 2/14/19

Nemus Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address global medical indications, announced today that it has signed an agreement with Pharmaceuticals International Inc. (Pii), a contract development manufacturing organization (CDMO) to develop a sterile eyedrop dosage formulation of NB1111 for human dosing.  NB1111 is Nemus’ proprietary prodrug of tetrahydrocannabinol (THC) that is currently undergoing development for the treatment of glaucoma.

“Pii is an experienced formulator of ocular-based therapies and we look forward to working with them, and our discovery and research colleagues at the University of Mississippi, to advance a clinical-grade formulation of NB1111 into the clinic,” noted Brian Murphy, MD, CEO and Chief Medical Officer of Nemus. “The Company plans to conduct a first-in-human, single-ascending dose clinical trial in Australia among patients with mild to moderate glaucoma.”
 
“We look forward to partnering with Nemus to develop an ophthalmic formulation of NB1111 as an improved treatment option for patients with glaucoma. Pii’s extensive product development expertise will be an invaluable contributor to ensuring on-time delivery of the NB1111 formulation for evaluation in the planned clinical trial,” added Dr. Kurt Nielsen, Pii’s President and CEO.

About Pharmaceutics International, Inc.
Pii is a privately held CDMO providing dosage form development and cGMP manufacturing services to the global pharmaceutical industry. Headquartered in Hunt Valley, Maryland, USA, Pii's services include pre-formulation development, and clinical and commercial cGMP manufacturing of parenterals, liquid solutions and oral solids, including soft gels, tablets and capsules. In addition, the Company offers containment suites to handle potent drugs and Schedules I-V controlled substances. 
For more information, please visit www.pharm-int.com.

About Nemus Bioscience, Inc.
The Company is a biopharmaceutical company, headquartered in Long Beach, California, focused on the discovery, development, and commercialization of bioengineered cannabinoid-based therapeutics for significant unmet medical needs in global markets. With proprietary technology licensed from the University of Mississippi, Nemus is developing novel ways to deliver cannabinoid-based drugs for specific indications with the aim of optimizing the clinical effects of such drugs while limiting potential adverse events. Nemus' strategy is to explore the use of proprietary biosynthetic compounds, alone or in combination with corporate partners.

Nemus is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.

For more information, visit www.nemusbioscience.com.

Nemus Bioscience Signs Agreement with Noramco to Manufacture Proprietary Cannabidiol Analog

Source:  Nemus Bioscience, Inc. 3/4/19

Enhanced Bioavailability Could Prove Pivotal in Providing Neuroprotection in Diseases of the Retina


Nemus Bioscience, Inc. (OTCQB: NMUS), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced an agreement with Noramco, Inc. (Noramco) for the manufacturing and scale-up of Nemus’ proprietary analog of cannabidiol (CBD) licensed from the University of Mississippi.  Noramco is a recognized, global producer and provider of controlled substances, including cannabinoids, to the pharmaceutical industry.

Unlike a prodrug which must be metabolized into the active drug form, an analog has its own intrinsic pharmaceutical activity.  Early animal studies of the analog, cannabidiol-valine-hemisuccinate (CBDVHS), have demonstrated improved bioavailability when compared to CBD, based on chemical modifications to the molecule utilizing amide ester bioengineering developed at the University of Mississippi. These attributes, including cannabinoid-based neuroprotection, could be especially important in ocular diseases, where penetrance into the posterior chamber of the eye could potentially expand therapeutic options into diseases of the retina, like macular degeneration and diabetic retinopathy.

 “Noramco is looking forward to working with Nemus and helping to advance the unique analog CBDVHS through process development and cGMP manufacturing,” commented Bill Grubb, Chief Innovation Officer and Vice-President of Global Business Development.

“Contracting with Noramco signals the launch of the CBD-analog program to advance this candidate molecule into pre-clinical development, with a near-term goal to conduct clinical trials to address diseases of the eye,” noted Brian Murphy, M.D., CEO-CMO of Nemus. “Noramco has particular expertise in working with cannabidiol and CBD-derivatives, making them a strategic part of the CBDVHS development plan.”

About Noramco
Noramco, headquartered in Wilmington, Delaware, is a leading North American producer of controlled substances bulk Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry. The company offers cannabinoids and other APIs for use in abuse deterrence, attention deficit disorder, pain management, and addiction management. Established in 1979, Noramco maintains production and R&D facilities in Delaware and Georgia (USA); and Neuhausen, Switzerland; and accesses agricultural operations in Tasmania through an affiliate, Tasmanian Alkaloids. Additional information about Noramco can be obtained by visiting Noramco’s web site at www.Noramco.com

About Nemus Bioscience, Inc.
Nemus is a biopharmaceutical company, headquartered in Long Beach, California, focused on the discovery, development, and commercialization of bioengineered cannabinoid-based therapeutics for significant unmet medical needs in global markets. With proprietary technology licensed from the University of Mississippi, Nemus is developing novel ways to deliver cannabinoid-based drugs for specific indications with the aim of optimizing the clinical effects of such drugs while limiting potential adverse events. Nemus' strategy is to explore the use of proprietary synthetic compounds, alone or in combination with corporate partners.

Nemus is part of the Emerald Health group, which comprises multiple companies focused on developing pharmaceutical, botanical, and nutraceutical products  providing wellness and medical benefits by interacting with the human body’s endocannabinoid system.

For more information, visit www.nemusbioscience.com

Nemus Bioscience Confirms NB1111 Mechanism of Action and Reports Positive Results from Glaucoma Biomarker Studies in Human Donor Tissues

Source:  Nemus Bioscience, Inc. 3/12/19


Prodrug of THC Improves Fluid Outflow Across Trabecular Meshwork and Positively Impacts Disease Markers Associated with Glaucoma-Related Fibrosis and Inflammation

Changes in Neovascularization Markers Indicate Potential Utility of NB1111 in Diabetic Retinopathy and Macular Degeneration  


Nemus Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on developing bioengineered cannabinoid-based therapeutics to address global medical indications, announced today that data generated by Glauconix Biosciences, Inc. has validated the mechanism of action of NB1111, Nemus’ proprietary prodrug of tetrahydrocannabinol (THC-valine-hemisuccinate, or THCVHS), in lowering intraocular pressure (IOP), a defining symptom of hypertensive glaucoma.

The analyses involved a laboratory model using human donor cells that contained the ocular tissue responsible for helping to regulate intraocular pressure, the trabecular meshwork. The studies included a comparison of the activity of tetrahydrocannabinol (THC), the biologically active part of NB1111, in facilitating fluid drainage resulting in lower IOP as well as lowering levels of biomarker molecules associated with inflammation and fibrosis, two processes associated with tissues that are damaged in a disease setting – including glaucoma and other ocular disorders

Researchers have previously demonstrated that ocular tissues possess a high degree of cannabinoid receptors, especially on organs that help regulate IOP. Given that THC binds both types of cannabinoid receptors, these data point to a unique mechanism of action whereby the ability of THC to bind to cannabinoid receptors results in a beneficial decline in IOP due to enhanced fluid drainage. When IOP is left unchecked, there is often damage to the optic nerve, leading to irreversible vision loss.

Additionally, biomarkers associated with inflammation and fibrosis in tissues affected by glaucoma were significantly decreased, pointing to anti-inflammatory and anti-fibrotic activities that are often associated with the cannabinoid class of molecules in other disease-states.

The studies also demonstrated that two biomarkers associated with neovascularization, a process of new blood vessel formation that can lead to vision loss or retinal detachment, were significantly lowered by exposure to THC. Neovascularization is often associated with diabetic retinopathy and macular degeneration, two leading causes of blindness, especially in older adults.

“The Glauconix Biosciences’ 3D-HTM™ technology was designed to help accelerate drug development by using bioengineered human donor 3D tissue models for target identification and validation, high throughput screening, and drug efficacy with physiological endpoints, such as fluid outflow,” commented Karen Torrejon, Ph.D., Founder and Chief Scientific Officer of Glauconix. “Historically, our technology has exhibited significant predictive value in assessing a drug candidate’s utility and likelihood of clinical success. Nemus’ data helps to provide a rationale for cannabinoid activity in lowering IOP and indicates a potential for the advancement of NB1111 into clinical testing.”

“These studies were significant across a spectrum of findings and we plan on submitting the data to an upcoming major ophthalmology meeting. Micro-quantities of cannabinoid delivered directly into the eye could have the dual benefit of a therapeutic effect while mitigating risk of systemic adverse events through direct tissue targeting, an advantage associated with using bioengineered molecules,” remarked Brian Murphy, MD, CEO and Chief Medical Officer of Nemus. “The impact on markers of ocular neovascularization also reinforces our commitment to test our cannabinoid-based ocular platform of NB1111, the prodrug of THC, and NB2222, the analog of cannabidiol (CBD), in ocular indications beyond glaucoma.”

About Glauconix Biosciences
Glauconix Biosciences is a leading developer of ophthalmic ex-vivo dynamic 3D human tissue models for accelerating therapeutic innovation and drug discovery. Their 3D tissue models can de-risk ophthalmic assets and expedite drug development. Glauconix adds value to their clients and partners by expediting early identification and validation of effective compounds or biologics in the preclinical phase and those entering clinical trials. To learn more about Glauconix Biosciences, visit www.glauconix-biosciences.com

About Nemus Bioscience, Inc.
The Company is a biopharmaceutical company, headquartered in Long Beach, California, focused on the discovery, development, and commercialization of bioengineered cannabinoid-based therapeutics for significant unmet medical needs in global markets. With proprietary technology licensed from the University of Mississippi, Nemus is developing novel ways to deliver cannabinoid-based drugs for specific indications with the aim of optimizing the clinical effects of such drugs while limiting potential adverse events. Nemus' strategy is to explore the use of proprietary biosynthetic compounds, alone or in combination with corporate partners.

Nemus is part of the Emerald Health group, which comprises multiple companies focused on developing pharmaceutical, botanical, and nutraceutical products providing wellness and medical benefits by interacting with the human body’s endocannabinoid system.

For more information, visit www.nemusbioscience.com.

Nemus Bioscience Reports Nanoemulsion of NB1111 Superior to First-Line Therapy, Latanoprost, in Lowering Intraocular Pressure in Validated Normotensive Animal Model Testing

Source:  Nemus Bioscience, Inc. 3/18/19

Nemus Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on developing bioengineered cannabinoid-based therapeutics to address global medical indications, announced today that NB1111, its prodrug of tetrahydrocannabinol (THC-valine-hemisuccinate; THCVHS), was statistically superior in lowering intraocular pressure (IOP) compared to the prostaglandin-based therapy, latanoprost, the current standard-of-care for treating glaucoma, across multiple timepoints during a seven-day course of repeated dosing using a validated rabbit normotensive ocular model. The experiments were performed by researchers at the University of Mississippi.

A proprietary nanoemulsion formulation developed by the University and used in these experiments extended the pharmaceutical activity time beyond eight-hours, supporting potential human dosing of once- to twice-daily, depending on time of administration.  These results are part of a portfolio of data from multiple sources that highlight the numerous beneficial attributes of Nemus’ cannabinoid-based prodrug as a potential treatment for glaucoma and other eye diseases. These data to-date have demonstrated:

• THCVHS is a true prodrug of THC and is converted in vitro and in vivo to THC
• The patented bioengineering associated with THCVHS results in a superior capability to enter both the anterior and posterior compartments of the eye, which permits interaction with cannabinoid receptors involved in regulating IOP, while THC alone is not capable of effectively entering the eye.
• The scientific literature shows that the eye possesses an elevated density of cannabinoid receptors in all compartments, especially on organs that regulate IOP and tissues that comprise the retina
• THC derived from THCVHS, by activating cannabinoid receptors, results in increased fluid drainage from both the normal and glaucomatous eye via enhanced channel opening through vessel dilation and anti-inflammatory/anti-fibrotic activities
• THCVHS in a standard eyedrop lowered IOP significantly better than pilocarpine and timolol, established glaucoma drugs, with an average decline of 45% in a high-IOP animal model
• THCVHS in a solid lipid nanoparticle (SLN), a precursor to the nanoemulsion formulation, was able to attain higher concentrations of the drug into the eye, especially the posterior compartment where retinal ganglion cells that comprise the optic nerve reside
• THC in ex vivo testing, using human donor cells, resulted in a significant decline in biomarkers associated with inflammatory and fibrotic reactions as well as reduced neovascularization biomarkers, pointing to potential utility in treating diseases that cause damage to the retina, like macular degeneration and diabetic retinopathy
• Literature shows that THC has direct neuroprotective activity on retinal ganglion cells across multiple species of animals, including primates. Nerve death is the central disease process associated with irreversible vision loss in glaucoma

“The current experiment demonstrated that both single and multiple applications of a nanoemulsion formulation of NB1111 significantly lowered IOP when compared to latanoprost,” noted Soumyajit Majumdar, PhD, Professor of Pharmaceutics and Drug Delivery and Associate Dean for Research and Graduate Programs in the School of Pharmacy at the university, and lead scientist of the ophthalmic research of NB1111. “NB1111 has been shown in animal studies to deliver superior IOP-lowering capability when compared to the major generic medications currently approved for glaucoma: latanoprost, timolol and pilocarpine. Our approach, using direct ocular delivery, is consistent with the American Academy of Ophthalmology recommendation against cannabis use to manage glaucoma. We look forward to continuing ocular research in other disease processes using THCVHS, as well as human testing of this prodrug.”

“We plan on submitting this data to an upcoming peer-reviewed ophthalmology meeting while continuing to advance the final formulation for NB1111 based on these pivotal studies conducted by the University and the discovery work by Dr. Mahmoud ElSohly, professor at the National Center for Natural Products Research at the University of Mississippi School of Pharmacy and co-inventor of THCVHS. In addition to preparing for first-in-human clinical trials, Nemus also plans on conducting direct retinal neuroprotection studies utilizing NB1111 as well as the cannabidiol analog, CBD-valine-hemisuccinate,” stated Brian Murphy, MD, CEO and Chief Medical Officer of Nemus. “The underlying principle of this work is to leverage bioengineered cannabinoids to develop a therapeutic portfolio based on precision medicine: delivering the needed cannabinoid directly to the target tissue to optimize both safety and efficacy.”

About Glaucoma
Glaucoma is a leading cause of blindness with more than 70 million patients affected worldwide. The market for glaucoma drugs is projected to be approximately $6.6 billion in 2023 but could rise further with the introduction of innovative therapies into Asian markets like China and India. (MarketScope).  Lowering intraocular pressure is the current mainstay of therapy.  Newer innovative therapeutics, particularly cannabinoid-based drug candidates, look to prevent vision loss through direct neuroprotection of the retinal ganglion cells that comprise the optic nerve.

About the University of Mississippi
The University of Mississippi, the state's flagship institution, is among the elite group of R-1: Doctoral Universities - Highest Research Activity in the Carnegie Classification. The university has a long history of producing leaders in public service, academics, research and business. Its 15 academic divisions include a major medical school, nationally recognized schools of accountancy, law and pharmacy, and an Honors College acclaimed for a blend of academic rigor, experiential learning and opportunities for community action.

About Nemus Bioscience, Inc.
The Company is a biopharmaceutical company, headquartered in Long Beach, California, focused on the discovery, development, and commercialization of bioengineered cannabinoid-based therapeutics for significant unmet medical needs in global markets. With proprietary technology licensed from the University of Mississippi, Nemus is developing novel ways to deliver cannabinoid-based drugs for specific indications with the aim of optimizing the clinical effects of such drugs while limiting potential adverse events. Nemus' strategy is to explore the use of proprietary biosynthetic compounds, alone or in combination with corporate partners.

Nemus is part of the Emerald Health group, which comprises multiple companies focused on developing pharmaceutical, botanical, and nutraceutical products providing wellness and medical benefits by interacting with the human body’s endocannabinoid system.

For more information, visit www.nemusbioscience.com.

SanSal Wellness Holdings, Inc. Announces Name Change to Veritas Farms, Inc. and Trading Symbol Change to VFRM

Source:  Veritas Farms, Inc. 2/4/19

SanSal Wellness Holdings, Inc. (the “Company”) (OTCQB: SSWH), a vertically integrated agribusiness focused on producing full spectrum natural phytocannabinoid-rich industrial hemp extracts, is pleased to announce that the Company has changed its name to “Veritas Farms, Inc.”

In connection with the name change, effective with the market open on Tuesday, February 5, 2019, the Company’s common stock will commence trading on the OTCQB under the new stock ticker symbol “VFRM”.  The new CUSIP number for the Company’s common stock is 92347N108.

Derek Thomas, Vice President of Business Development of Veritas Farms, Inc., commented, “This corporate name change is an important step forward to expand and leverage our established Veritas Farms™ hemp extract products brand with consumers, distributors, partners, investors, and the media.  We anticipate this will enable the Company to build a readily identifiable and memorable high-quality brand in the rapidly growing and quickly evolving industrial hemp extract sector.”

Veritas Farms™ full spectrum hemp extract products include vegan capsules, tinctures, formulations for sublingual applications and infused edibles, lotions, salves, vape oils and pre-filled vape cartridges, and oral syringes in a variety of size formats and flavors.  All Veritas Farms™ brand products are third-party laboratory tested for strength and purity.

For additional information and product purchase, visit www.sansalwellness.com and www.theveritasfarms.com.

About the Company
Veritas Farms, Inc. f/k/a SanSal Wellness Holdings, Inc. (OTCQB: SSWH) is a vertically integrated agribusiness focused on producing superior quality, whole-plant, broad spectrum phytocannabinoid-rich hemp oils and extracts.  The Company currently operates a 140-acre farm and production facilities in Pueblo, Colorado, and is registered with the Colorado Department of Agriculture to grow industrial hemp. The Company markets and sells products under its Veritas Farms™ brand and manufactures private label products for a number of leading distributors and retailers.  The Company files periodic reports with the Securities and Exchange Commission, which can be viewed at www.sec.gov.

Veritas Farms. Inc. (VFRM) Reports Record Preliminary 4th Quarter Revenue and Gross Profit

Source:  Veritas Farms, Inc.  3/6/19

Veritas Farms, Inc. (the “Company” or “Veritas Farms”) (OTCQB: VFRM), a vertically integrated agribusiness focused on the production of full spectrum hemp extracts with naturally occurring cannabinoids, is pleased to release these selected preliminary unaudited 4th Quarter 2018 financial results.

Selected Preliminary Unaudited 4th Quarter 2018 Financial Highlights - Veritas Farms, Inc.
• Total Revenue: $961,929, up from $355,653, an increase of 170% from Q4 2017.
• Total Cost of Goods Sold: $311,752, down from $555,932, a decrease of 44% form Q4 2017
• Gross Profit: $650,177, up from a loss of $200,278 in Q4 2017, an increase of $850,455
• Total Inventory: $2,295,943, up from $1,428,758, an increase of 61% from Q4 2017
• Total Accounts Payable: $163,627, down from $245,082, a decrease of 33% from Q4 2017
• Total Liabilities: $800,693, down from $2,102,454, a decrease of 62% from Q4 2017


Alexander M. Salgado, CEO and co-founder of Veritas Farms, commented, “As we continue to emerge as one of the leading fully-integrated full spectrum industrial hemp extract companies in the country, this past fourth quarter’s results have been our best ever with large increases in total revenue, gross profits, and inventory levels, while at the same time, reducing our cost of goods, accounts payable, and total liabilities.  When compared to our fourth quarter numbers from last year, our growth has been remarkable.

“This outstanding growth rate is not restricted to our year-over-year results.  Compared to our previously reported quarterly period, Q3 2018, our total revenues more than doubled by 109% and gross profits jumped by over 645%.

“These accomplishments were the direct result of the hard work of our dedicated team and partners, along with significant new capital investments at our Colorado facility, the successful launch of our own Veritas Farms™ branded product line, and our targeted sales and marketing programs.” 

Mr. Salgado concluded, “Following the signing of the 2018 United States Farm Bill in late December 2018 by President Trump that provided a federal legal framework for industrial hemp, we expect that our growth and expansion plans will continue to gain momentum throughout 2019 as more and more mainstream retailers, drug stores, and health care providers begin to sell and promote hemp extract products to their customers across the country.”

Veritas Farms expects to report audited full year 2018 results in its Annual Report on Form 10-K, to be filed on or before mid-April 2019.

About Veritas Farms, Inc.
Veritas Farms, Inc. (OTCQB: VFRM) is a vertically integrated agribusiness focused on producing superior quality, whole plant, full spectrum hemp oils and extracts containing naturally occurring cannabinoids.  The Company currently operates a 140-acre farm and production facilities in Pueblo, Colorado, and is registered with the Colorado Department of Agriculture to grow industrial hemp.  The Company markets and sells products under its Veritas Farms™ brand and manufactures private label products for a number of leading distributors and retailers. 

Veritas Farms™ brand full spectrum hemp extract products include vegan capsules, tinctures, formulations for sublingual applications and infused edibles, lotions, salves, and oral syringes in a variety of size formats and flavors.  All Veritas Farms™ brand products are third-party laboratory tested for strength and purity.  The Company files periodic reports with the Securities and Exchange Commission, which can be viewed at www.sec.gov.

For additional information and online product purchase, visit www.theveritasfarms.com.

Veritas Farms, Inc. (VFRM) Enters Exclusive Agreement with Affiliate of the Nations Largest Home Respiratory & Sleep Diagnostics Provider to Provide Custom Formulation and Manufacturing

Source:  Veritas Farms, Inc. 2/27/19

eritas Farms, Inc. (the “Company”) (OTCQB: VFRM), a vertically integrated agribusiness focused on the production of full spectrum hemp extracts with naturally occurring cannabinoids, has entered into an exclusive formulation and manufacturing agreement with PurWell, LLC (“PurWell”), an affiliate of VirtuOx, Inc. (“VirtuOx”), the nation’s largest home respiratory and sleep diagnostics provider with over 30,000 new patients each month.

Under the Agreement, Veritas Farms will manufacture a custom formulated line of hemp extract products for PurWell to be sold under the PūrWell brand.  The products will include PūrSlēp, a full spectrum hemp oil combined with a proprietary blend of holistic natural supplements widely known to promote effective sleep.

Alexander M. Salgado, CEO and co-founder of Veritas Farms, Inc., commented, “As an affiliate of the nation’s largest home respiratory and sleep diagnostics provider, we are excited to work with PurWell as exclusive formulation and manufacturing partner for PūrSlēp and the PūrWell brand that was recently launched online and at select healthcare providers across the country.  We look forward to providing them a consistent and dependable supply of our best-in-class full spectrum hemp oil products and being an important part of their long-term success.”

Formulated and manufactured at the Veritas Farms grow, processing, and production facilities in Pueblo, Colorado, without the use of any pesticides, herbicides, or fungicides, each batch of PūrSlēp and the entire PūrWell line of products will be laboratory tested for purity and potency.  PūrSlēp’s formulation includes full spectrum hemp oil, GABA, hops flower extract, valerian root, chamomile flower extract, l-tryptophan, melatonin, MCT oil, and organic essential oil.  PūrSlēp is vegan, sugar-free, gluten free, and alcohol-free, and it contains no artificial colors or flavors.  

PūrSlēp is available online now at www.purwell.com and at select physician’s offices, pharmacies, and medical equipment retailer locations.  

About VirtuOx, Inc. and PurWell, LLC

VirtuOx, Inc. (www.virtuox.net) is the nation’s largest home respiratory and sleep diagnostics provider, testing 30,000+ new patients each month for conditions such as sleep apnea, insomnia, and cardiac arrythmias.  VirtuOx Inc. has received full accreditation by The Joint Commission as an Ambulatory Care Sleep Diagnostic Center.

PūrWell, LLC. (www.purwell.com) is dedicated to making high quality, reliable Full Spectrum Hemp Oil products for the healthcare marketplace.  PūrWell offers physicians and other healthcare professionals the ability to sell Full Spectrum Hemp Oil products through the industry’s only zero cost-of-entry sales model.  For more information, send inquiries to info@purwell.com. 

About Veritas Farms, Inc.

Veritas Farms, Inc. (OTCQB: VFRM) is a vertically integrated agribusiness focused on producing superior quality, whole plant, full spectrum hemp oils and extracts containing naturally occurring cannabinoids.  The Company currently operates a 140-acre farm and production facilities in Pueblo, Colorado, and is registered with the Colorado Department of Agriculture to grow industrial hemp. The Company markets and sells products under its Veritas Farms™ brand and manufactures private label products for a number of leading distributors and retailers.  

Veritas Farms™ brand full spectrum hemp extract products include vegan capsules, tinctures, formulations for sublingual applications and infused edibles, lotions, salves, and oral syringes in a variety of size formats and flavors.  All Veritas Farms™ brand products are third-party laboratory tested for strength and purity.  The Company files periodic reports with the Securities and Exchange Commission, which can be viewed at www.sec.gov.

For additional information and online product purchase, visit www.theveritasfarms.com.